Conducting Remote Clinical Trials Productively During a Pandemic

With more than 75% of clinical trials disrupted due to the COVID-19 pandemic, many biopharma companies are applying virtual components (telehealth, home health visits instead of site visits, wearables, etc.) in efforts to resume clinical studies. This has accelerated a massive shift in adopting emerging technologies that have been on conference agendas for over a decade. Even as trial disruptions are leveling off and companies are planning a “return to normal” in the coming months, many anticipate that eClinical tools will continue to be used after the pandemic is under control. Investors are also paying attention, placing investments in eClinical solutions companies and betting on the $50B (and growing) clinical trials market. Through use of technology, programs are also improving access to trials and increasing participation. How have remote trials affected investor outlook and are there changes to valuations and risk assessments? Hear from diverse perspectives on how digital tools are allowing drug developers to continue their programs and how the coming decade may shake out for clinical trials.